Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic gamma9delta2 T cells
- Development stage
- Phase 1
- Lead developer
- The First Affiliated Hospital of USTC
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic gamma9delta2 (γ9δ2) T cells is an investigational adoptive cell therapy being developed by Anhui Provincial Hospital (the First Affiliated Hospital of USTC) for the treatment of recurrent hematologic malignancies following allogeneic hematopoietic stem cell transplantation (allo-HSCT). γ9δ2 T cells are a unique subset of T lymphocytes that bridge innate and adaptive immunity, capable of recognizing and killing tumor cells in an MHC-independent manner. This recognition is primarily mediated through the γ9δ2 T-cell receptor (TCR), which detects phosphoantigens, and natural killer receptors such as NKG2D, which recognize stress-induced ligands on malignant cells. Because their activation is not MHC-restricted, these cells carry a lower risk of inducing graft-versus-host disease (GvHD) compared to conventional alpha-beta T cells, making them suitable for allogeneic applications. The therapy is currently being evaluated in Phase 1 clinical trials to assess safety, tolerance, and the potential to induce a graft-versus-leukemia effect.
- Other names
- allogeneic γ9δ2 T cellsallogeneic gamma 9 delta 2 T cells
02
Targets
BTN2A1 (Butyrophilin subfamily 2 member A1)BTN3A1 (Butyrophilin subfamily 3 member A1)
Beyond the preview
Go deeper on allogeneic gamma9delta2 T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic gamma9delta2 T cells.